We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength?
Read MoreHide Full Article
Tempus AI (TEM - Free Report) shares rallied 14.9% in the last trading session to close at $80.36. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% gain over the past four weeks.
Tempus scored a strong price increase on investors’ optimism surrounding the company’s plan to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. This will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built around disease populations and patient outcomes, specifically optimized for AI-driven research.
This health care technology company is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +36.4%. Revenues are expected to be $411.75 million, up 23.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Tempus, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TEM going forward to see if this recent jump can turn into more strength down the road.
Tempus is a member of the Zacks Medical Info Systems industry. One other stock in the same industry, Omnicell (OMCL - Free Report) , finished the last trading session 0.6% higher at $32.62. OMCL has returned -11% over the past month.
For Omnicell, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.42. This represents a change of -17.7% from what the company reported a year ago. Omnicell currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength?
Tempus AI (TEM - Free Report) shares rallied 14.9% in the last trading session to close at $80.36. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% gain over the past four weeks.
Tempus scored a strong price increase on investors’ optimism surrounding the company’s plan to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. This will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built around disease populations and patient outcomes, specifically optimized for AI-driven research.
This health care technology company is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +36.4%. Revenues are expected to be $411.75 million, up 23.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Tempus, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TEM going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Tempus is a member of the Zacks Medical Info Systems industry. One other stock in the same industry, Omnicell (OMCL - Free Report) , finished the last trading session 0.6% higher at $32.62. OMCL has returned -11% over the past month.
For Omnicell, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.42. This represents a change of -17.7% from what the company reported a year ago. Omnicell currently has a Zacks Rank of #3 (Hold).